Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
CONCLUSIONS: The existing literature does not suffice for assessing whether Lopinavir/ritonavir has any benefit in SARS, MERS or COVID-19.
PMID: 32894567 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Coronavirus | COVID-19 | Databases & Libraries | Drugs & Pharmacology | Kaletra | MERS | Middle East Health | Norvir | Respiratory Medicine | SARS | Study